With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.60787-05-5,1-(4-Methylpiperazin-1-yl)ethanone,as a common compound, the synthetic route is as follows.,60787-05-5
To a solution of 1 -(4-methylpiperazin-1 -yl)ethanone (1 .68 g, 1 1 .8 mmol) in THF (25 mL) cooled to -78 C, a solution of LDA (1 .5 M in THF, 9.8 mL, 14.75 mmol) was added, and the resulting mixture was stirred at -78 ^ for 1 h under argon atmosphere. Finally, a solution of 4-bromoindan-1 -one (1 .25 g, 5.9 mmol) in THF (50 mL) was added, and the resulting mixture was kept at -78 ‘ for 4 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic extracts were dried over Na2S04 and evaporated to dryness. A solution of the previous residue in AcOH:H2S04:H20 (79 mL, 85:10:5) was stirred for 6 h. The reaction mixture was poured into water, basified with 50% NaOH and extracted with EtOAc. The organic extract, after being dried over Na2S04, was evaporated to dryness. To a solution of the previous residue in THF (75 mL) cooled to 0 C, AIH3- NMe2Et (0.5 M in toluene, 20 mL, 10.34 mmol) was added and the resulting mixture was stirred for 5 h. EtOAc:H20 (90 mL, 1 :1 ) was added to the reaction mixture and the resulting suspension was filtered through Celite. The layers were separated and the aqueous phase was extracted with EtOAc. The organic extract was dried over Na2S04 and evaporated to dryness. A solution of the previous residue in 37% HCLEtOH (150 mL, 1 :1 ) was refluxed overnight. The reaction mixture was evaporated to dryness. Purification of the residue by silica gel column chromatography (EtOAc/NH3:MeOH mixtures of increasing polarity as eluent) afforded the desired product (981 mg, 51 %). 1 H-NMR (CDCI3, 300 MHz) delta: 7.32 (m, 2H), 7.18 (t, J= 7.6 Hz, 1 H), 6.30 (s, 1 H), 3.31 (d, J= 1 .8 Hz, 2H), 2.72 (m, 4H), 2.60 (m, 4H), 2.51 (m, 4H), 2.30 (s, 3H) ppm. EI-MS m/z: 320.1 (M).
As the paragraph descriping shows that 60787-05-5 is playing an increasingly important role.
Reference£º
Patent; LABORATORIOS DEL DR. ESTEVE, S.A.; ALCALDE-PAIS, Maria, de las Ermitas; ALMANSA-ROSALES, Carmen; DIAZ-FERNANDEZ, Jose-Luis; MESQUIDA-ESTEVEZ, Maria, de les Neus; PALOMA-ROMEU, Laura; WO2014/6071; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics